P
US10201596B2ActiveUtilityPatentIndex 83

Peptide conjugated particles for the treatment of allergy

Assignee: UNIV NORTHWESTERNPriority: Jun 21, 2012Filed: Jun 21, 2013Granted: Feb 12, 2019
Est. expiryJun 21, 2032(~6 yrs left)· nominal 20-yr term from priority
Inventors:SHEA LONNIE DMILLER STEPHEN DYAP JONATHAN WOON TECKGETTS DANIEL RMCCARTHY DERRICK
A61P 37/08A61P 37/00A61P 37/06A61K 39/39A61K 2039/55555A61K 9/1271A61K 2039/6093A61K 39/385A61K 47/6937A61K 9/127A61K 2039/577A61K 39/001A61K 39/35A61K 39/0005A61K 9/1647A61K 39/0008A61K 39/395
83
PatentIndex Score
4
Cited by
175
References
21
Claims

Abstract

The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A method for the treatment of allergy or reduction-of an allergic reaction in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising an allergen encapsulated within a carboxylated poly(lactic-co-glycolic acid) (PLGA) particle with a negative zeta potential between −100 and −30 mV. 
     
     
       2. The method of  claim 1 , wherein the zeta potential of the particle is from about −100 mV to about −40 mV. 
     
     
       3. The method of  claim 1 , wherein the zeta potential of the particle is from about −50 mV to about −40 mV. 
     
     
       4. The method of  claim 1 , wherein the particle has a diameter of between about 0.1 μm to about 10 μm. 
     
     
       5. The method of  claim 1 , wherein the particle has a diameter of between about 0.5 μm to about 1 μm. 
     
     
       6. The method of  claim 1 , wherein the particle has a diameter of about 0.5 μm. 
     
     
       7. The method of  claim 1 , wherein said allergen is an environmental allergen or a food allergen. 
     
     
       8. The method of  claim 1 , wherein said allergen comprises all or at least a portion of a protein selected from the group consisting of: ragweed pollen proteins, hair follicle antigen, human tropomyosin isoform 5, Bahia grass pollen (BaGP), peach allergen Pru p 3, alpha s 1-Caein Milk allergen, Apig1 celery allergen, Berel Brazil nut allergen, B-Lactoglobulin Milk allergen, Bovine serum albumin, Cor a 1.04 Hazelnut allergen, and Ovalbumin Egg allergen. 
     
     
       9. The method of  claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. 
     
     
       10. The method of  claim 1 , wherein the pharmaceutical composition is administered orally, nasally, intravenously, intramuscularly, ocularly, transdermally, intraperitoneally, or subcutaneously. 
     
     
       11. The method of  claim 1 , wherein the pharmaceutical composition is administered intravenously. 
     
     
       12. The method of  claim 1 , wherein the PLGA particle further comprises an apoptosis signaling molecule. 
     
     
       13. The method of  claim 12 , wherein the apoptosis signaling molecule is attached to the surface of the PLGA particle. 
     
     
       14. The method of  claim 13 , wherein the apoptosis signaling molecule is phosphatidyl serine annexin-1, annexin-5, milk fat globule-EGF-factor 8 (MFG-E8) or a thrombospondin. 
     
     
       15. A method for the treatment or prevention of an allergy in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising an allergen encapsulated within a carboxylated poly(lactic-co-glycolic acid) (PLGA) particle with a zeta potential from about −40 mV to about −50 mV and a diameter of about 0.5 μm to about 1.0 μm and a pharmaceutically acceptable carrier. 
     
     
       16. The method of  claim 15 , wherein said allergen is an environmental allergen or a food allergen. 
     
     
       17. The method of  claim 15 , wherein said allergen comprises all or at least a portion of a protein selected from the group consisting of: ragweed pollen proteins, hair follicle antigen, human tropomyosin isoform 5, Bahia grass pollen (BaGP), peach allergen Pru p 3, alpha s 1-Caein Milk allergen, Apig1 celery allergen, Berel Brazil nut allergen, B-Lactoglobulin Milk allergen, Bovine serum albumin, Cor a 1.04 Hazelnut allergen, and Ovalbumin Egg allergen. 
     
     
       18. The method of  claim 15 , wherein the pharmaceutical composition is administered orally, nasally, intravenously, intramuscularly, ocularly, transdermally, intraperitoneally, or subcutaneously. 
     
     
       19. The method of  claim 15 , wherein the PLGA particle further comprises an apoptosis signaling molecule conjugated on the particle surface. 
     
     
       20. The method of  claim 19 , wherein the apoptosis signaling molecule is phosphatidyl serine annexin-1, annexin-5, milk fat globule-EGF-factor 8 (MFG-E8) or a thrombospondin. 
     
     
       21. The method of  claim 1 , wherein the zeta potential of the particle is from about −50 mV to about −30 mV.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.